Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
Hair care & quick commerce shine
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
Subscribe To Our Newsletter & Stay Updated
